Article

Apolipoprotein E4 allele presence and functional outcome after severe traumatic brain injury.

University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania, USA.
Journal of Neurotrauma (Impact Factor: 3.97). 06/2007; 24(5):790-7. DOI: 10.1089/neu.2006.0133
Source: PubMed

ABSTRACT Presence of the apolipoprotein E (APOE) 4 allele has been associated with increased incidence and faster progression of neurodegenerative diseases, poorer recovery from neurologic insult, and decreased cognitive function in the well-elderly. The specific association between APOE genotype and recovery from severe traumatic brain injury (TBI) is conflicting with many groups finding the APOE 4 allele to be associated with poorer outcome while others have found no association. The purpose of this study was to investigate the association between APOE 4 allele presence and recovery during the two years after injury from severe TBI in light of other potential covariates, such as age, race, gender, hypotension or hypoxia before hospital admission and severity of injury. APOE genotype was determined for 123 subjects with severe TBI. Glasgow outcome score (GOS) and mortality were collected at 3, 6, 12, and 24 months after injury. Results showed individuals improved over the two year period following injury and those with the 4 allele had a slower recovery rate than those without the APOE 4 allele over the two year period. We did not however find significant differences in GOS at individual time points when controlling for other covariates. Our findings suggest that APOE 4 allele presence influences recovery rate from severe TBI independent of other covariates. The findings of this study are unique in that they address not only the relationship between APOE 4 allele presence and outcome from severe TBI, but also describe differences in trajectory of recovery by APOE 4 allele presence.

0 Followers
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is estimated that 2% of the population from industrialized countries live with lifelong disabilities resulting from traumatic brain injury (TBI) and roughly one in four adults are unable to return to work 1 year after injury because of physical or mental disabilities. TBI is a significant public health issue that causes substantial physical and economical repercussions for the individual and society. Electronic databases (PubMed, Web of Science, Google Scholar) were searched with the keywords traumatic brain injury, TBI, genes and TBI, TBI outcome, head injury. Human studies on non-penetrating traumatic brain injuries reported in English were included. To provide health care workers with the basic information for clinical management we summarize and compare the data on post-TBI outcome with regard to the impact of genetic variation: apolipoprotein E (APOE), brain-derived neurotrophic factor (BDNF), calcium channel, voltage dependent P/Q type, catechol-O-methyltransferase (COMT), dopamine receptor D2 and ankyrin repeat and kinase domain containing 1 (DRD2 and ANKK1), interleukin-1 (IL-1), interleukin-6 (IL-6), kidney and brain expressed protein (KIBRA), neurofilament, heavy polypeptide (NEFH), endothelial nitric oxide synthase 3 (NOS3), poly (ADP-ribose) polymerase-1 (PARP-1), protein phosphatase 3, catalytic subunit, gamma isozyme (PPP3CC), the serotonin transporter (5-HTT) gene solute carrier family 6 member (SLC6A4) and tumor protein 53 (TP53). It is evident that contradicting results are attributable to the heterogeneity of studies, thus further researches are warranted to effectively assess a relation between genetic traits and clinical outcome following traumatic injuries.
    The Neuroscientist 07/2014; DOI:10.1177/1073858414543150 · 7.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Traumatic brain injury (TBI) is a multi-factorial pathology with great inter-individual variability in response to injury and outcome. Mitochondria contain their own DNA (mtDNA) with genomic variants that have different physiological and pathological characteristics, including susceptibility to neurodegeneration. Given the central role of mitochondria in the pathophysiology of neurological injury, we hypothesized that its genomic variants may account for the variability in outcome following TBI. Methods: We undertook an analysis of mitochondrial haplogroups in a large, well-characterised cohort of 1094 TBI patients. A proportional odds model including age, brain CT characteristics, injury severity, pupillary reactivity, mitochondrial haplogroups and APOE was applied to Glasgow Outcome Score (GOS) data. Results: MtDNA had a significant association with 6-month GOS (p=0·008). Haplogroup K was significantly associated with favourable outcome (OR 1·64, CI 1·08-2·51; p=0·02). There was also a significant interaction between mitochondrial genome and age (p=0·002), with a strong protective effect of both haplogroups T (p=0·015) and K (p=0·017) with advancing age. We also found a strong interaction between APOE and mitochondrial haplogroups (p=0·001), indicating a protective effect of haplogroup K in carriers of the APOE ε4 allele. Interpretation: These findings reveal an interplay between mitochondrial DNA, pathophysiology of TBI and ageing. Haplogroups K and T, which share a common maternal ancestor, are shown as protective in TBI. The data also suggest that the APOE pathways interact with genetically-regulated mitochondrial functions in the response to acute injury, as previously reported in Alzheimer's disease. ANN NEUROL 2014. © 2014 American Neurological Association.
    Annals of Neurology 02/2014; 75(2). DOI:10.1002/ana.24116 · 11.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in the United States, and the incidence has been increasing within the geriatric age group as the population ages. There are many factors that are unique to this subgroup, including normal aging processes, differences in pathophysiology, and inherent medical comorbidities that affect their outcomes, treatment, and therefore, the allocation of medical and social services. The geriatric population has age-appropriate strength, coordination and balance deficits that make them predisposed to falls and subsequent TBI. The aging brain often has premorbid atrophy and increased susceptibility to the inflammatory, excitatory, and vascular processes that facilitate neurologic damage during the acute phases after injury. The aged also can have premorbid neurodegenerative and medical comorbidities that also affect their rehabilitation course, recovery, and outcomes once a TBI has occurred. Pharmacological strategies to maximize rehabilitation and recovery require specific considerations of the potential for adverse effects and contraindications specific to common comorbidities in the aged population. The management of geriatric TBI requires a coordinated effort between physicians and other healthcare providers with focus on risk factor modification, medical optimization, and successful return to the community by setting goals that emphasize level of function and quality of life.
    09/2012; 1(3). DOI:10.1007/s13670-012-0021-6